Jardiance drug class
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Jardiance Drug Class: Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors
Introduction to Jardiance (Empagliflozin)
Jardiance, known generically as empagliflozin, is a medication primarily used to manage type 2 diabetes mellitus (T2DM). It belongs to the drug class known as sodium-glucose cotransporter-2 (SGLT2) inhibitors, which are a relatively new and advanced class of antidiabetic drugs .
Mechanism of Action: SGLT2 Inhibition
Empagliflozin works by inhibiting the SGLT2 protein in the kidneys. This protein is responsible for reabsorbing glucose back into the bloodstream. By blocking SGLT2, empagliflozin promotes the excretion of glucose through urine, thereby lowering blood glucose levels without stimulating insulin release . This insulin-independent mechanism reduces the risk of hypoglycemia, a common side effect associated with many other antidiabetic medications .
Clinical Benefits Beyond Glycemic Control
Cardiovascular and Renal Protection
Empagliflozin has demonstrated significant cardiovascular and renal benefits. It has been shown to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with T2DM and established cardiovascular disease . Additionally, it helps in delaying the progression of chronic kidney disease (CKD) .
Weight Loss and Blood Pressure Reduction
Another advantage of empagliflozin is its ability to aid in weight loss and reduce blood pressure. The excretion of glucose results in a loss of calories, which can contribute to modest weight loss. Furthermore, the drug has been associated with slight reductions in systolic blood pressure, adding to its cardiovascular benefits .
Safety Profile and Side Effects
Common Side Effects
Empagliflozin is generally well tolerated, with most adverse events being mild to moderate in intensity. Common side effects include urinary tract infections and genital mycotic infections due to increased glucose in the urine .
Serious Risks
However, there are some serious risks associated with empagliflozin. One notable risk is euglycemic diabetic ketoacidosis (EDKA), a condition characterized by high levels of ketones in the blood despite normal blood glucose levels. This can occur under certain conditions such as acute illness or reduced carbohydrate intake . Additionally, there is a risk of acute kidney injury and impaired renal function.
Bioequivalence and Pharmacokinetics
Studies have shown that different formulations of empagliflozin, including the brand-name drug Jardiance, are bioequivalent. This means that they have similar pharmacokinetic properties and can be used interchangeably under fasting conditions .
Conclusion
Jardiance (empagliflozin) is a valuable addition to the therapeutic options for managing type 2 diabetes. Its unique mechanism of action as an SGLT2 inhibitor not only helps in controlling blood glucose levels but also offers additional benefits such as cardiovascular and renal protection, weight loss, and blood pressure reduction. While generally well tolerated, it is important to be aware of the potential serious risks, including euglycemic diabetic ketoacidosis and acute kidney injury. Overall, empagliflozin represents a significant advancement in the treatment of type 2 diabetes, particularly for patients at high cardiovascular risk.
Sources and full results
Most relevant research papers on this topic